• 1. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569
• 2. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 3. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 4. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 5. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738

Latest Research Insights on 2-(Pyridin-4-yl)acetic acid (CAS: 28356-58-3) in Chemical Biology and Pharmaceutical Applications

The compound 2-(Pyridin-4-yl)acetic acid (CAS: 28356-58-3) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile applications in drug discovery and development. This heterocyclic carboxylic acid derivative, characterized by a pyridine ring linked to an acetic acid moiety, serves as a key intermediate in the synthesis of bioactive molecules. Recent studies highlight its role in modulating enzyme activity, serving as a ligand for metal coordination complexes, and contributing to the design of novel therapeutic agents targeting inflammation, oncology, and infectious diseases.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of 2-(Pyridin-4-yl)acetic acid as a scaffold for developing inhibitors of histone deacetylases (HDACs), a class of enzymes implicated in cancer progression. Researchers utilized structure-activity relationship (SAR) analysis to optimize the compound's binding affinity, achieving nanomolar potency against HDAC6. The study further validated its selectivity profile using crystallographic data, revealing unique interactions with the enzyme's active site. These findings underscore its potential as a lead compound for oncology therapeutics.

In parallel, advancements in synthetic methodology have improved the accessibility of 2-(Pyridin-4-yl)acetic acid derivatives. A 2024 Organic Letters publication detailed a catalytic asymmetric synthesis route employing palladium-catalyzed C-H functionalization, achieving enantioselective yields exceeding 90%. This methodological breakthrough addresses prior challenges in stereocontrol, enabling the production of chiral analogs for probing biological targets with higher precision. Such innovations are critical for accelerating structure-based drug design campaigns.

Beyond small-molecule applications, 2-(Pyridin-4-yl)acetic acid has emerged as a versatile linker in bioconjugation strategies. A recent Bioconjugate Chemistry report highlighted its use in constructing antibody-drug conjugates (ADCs) via carbodiimide-mediated coupling to lysine residues. The resulting conjugates exhibited enhanced serum stability and tumor-specific payload release, attributed to the balanced hydrophilicity of the pyridine-acetate spacer. This application aligns with growing industry demand for next-generation ADC platforms.

Ongoing preclinical investigations are exploring the compound's immunomodulatory properties. Preliminary data presented at the 2024 American Chemical Society National Meeting revealed that 2-(Pyridin-4-yl)acetic acid derivatives can attenuate NLRP3 inflammasome activation in macrophages, suggesting potential applications in autoimmune disorders. Mechanistic studies identified interference with ASC speck formation as a putative mode of action, providing a new structural template for inflammasome-targeted therapeutics.

Quality control and analytical characterization remain active research areas for this compound. Recent pharmacopoeial updates (USP-NF 2024) have incorporated HPLC-UV methods for quantifying residual solvents and related substances in 2-(Pyridin-4-yl)acetic acid batches, reflecting its growing pharmaceutical relevance. These standardized protocols support Good Manufacturing Practice (GMP) compliance for scale-up production.

In conclusion, 2-(Pyridin-4-yl)acetic acid (CAS: 28356-58-3) exemplifies the convergence of synthetic chemistry and biological discovery. Its multifaceted applications—from enzyme inhibition to bioconjugation—position it as a valuable tool in modern drug development pipelines. Future research directions may explore its utility in PROTAC design and as a fragment for covalent inhibitor development, further expanding its impact on precision medicine initiatives.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)